argenx just committed up to $1.15bn to a biotech with no disclosed clinical drug. What is it really buying?
argenx will pay $550 million upfront to acquire Unnatural Products in a deal worth up to $1.15 billion, adding oral peptide discovery.
Pharma & Biotech